Clinical trial
Changes in Serum IGF-1 Levels With Resistance Exercises in Patients With Knee Osteoarthritis and Their Association With Clinical and Radiological Parameters
NCT07890155 is registered in ClinicalTrials.gov with Sisli Hamidiye Etfal Training and Research Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Changes in Serum IGF-1 Levels With Resistance Exercises in Patients With Knee Osteoarthritis and Their Association With Clinical and Radiological Parameters
- Lead sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- June 1, 2026
- Completion date
- January 31, 2027
- Enrollment
- 86 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metabolic syndrome (mets), osteoarthritis (knee)
Arms
As registered; 2 arms.
-
Metabolic Phenotype Group
Patients with knee osteoarthritis who meet the criteria for metabolic syndrome (metabolic phenotype). This group will undergo an 8-week supervised resistance exercise program.
-
Non-Metabolic Phenotype Group
Patients with knee osteoarthritis who do not meet the criteria for metabolic syndrome. This group will also undergo the exact same 8-week supervised resistance exercise program.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Serum Insulin-like Growth Factor 1 (IGF-1) Levels
Serum IGF-1 levels will be measured from fasting venous blood samples to evaluate the systemic anabolic response to the resistance exercise program.
Papers
PubMed papers this trial cites; 3 papers, results papers first, then newest first.
Lead sponsor's other trials
Sisli Hamidiye Etfal Training and Research Hospital, most recent start first.
+108 more trials See the organization page
Similar trials
Same condition (Metabolic Syndrome) and phase, most recent start first.
+1,164 more trials See the condition page